ATE249243T1 - Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat - Google Patents

Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat

Info

Publication number
ATE249243T1
ATE249243T1 AT97902867T AT97902867T ATE249243T1 AT E249243 T1 ATE249243 T1 AT E249243T1 AT 97902867 T AT97902867 T AT 97902867T AT 97902867 T AT97902867 T AT 97902867T AT E249243 T1 ATE249243 T1 AT E249243T1
Authority
AT
Austria
Prior art keywords
chelate
toxin
drug
antibodies
net load
Prior art date
Application number
AT97902867T
Other languages
English (en)
Inventor
Leslie A Khawli
Alan L Epstein
Original Assignee
Techniclone Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Techniclone Inc filed Critical Techniclone Inc
Application granted granted Critical
Publication of ATE249243T1 publication Critical patent/ATE249243T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT97902867T 1996-01-11 1997-01-06 Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat ATE249243T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58607596A 1996-01-11 1996-01-11
PCT/US1997/000307 WO1997025069A1 (en) 1996-01-11 1997-01-06 Antibodies with reduced net positive charge

Publications (1)

Publication Number Publication Date
ATE249243T1 true ATE249243T1 (de) 2003-09-15

Family

ID=24344206

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97902867T ATE249243T1 (de) 1996-01-11 1997-01-06 Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat

Country Status (10)

Country Link
EP (1) EP0873139B1 (de)
JP (2) JP2000503301A (de)
KR (1) KR100485240B1 (de)
AT (1) ATE249243T1 (de)
AU (1) AU730388B2 (de)
CA (1) CA2242750C (de)
DE (1) DE69724761T2 (de)
ES (1) ES2206683T3 (de)
RU (1) RU2219949C2 (de)
WO (1) WO1997025069A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047903A1 (en) * 2003-11-07 2005-05-26 Upstate Usa. Inc. A method for generating antibody conjugates that preserves antigen recognition
US20150344580A1 (en) * 2012-06-05 2015-12-03 Eldar Kim Human Monoclonal Antibodies Against Human Chemokine Receptor CCR7
BR112014030844A2 (pt) 2012-07-04 2019-10-15 Hoffmann La Roche anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo
JP6324376B2 (ja) 2012-07-04 2018-05-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗テオフィリン抗体および使用方法
BR112014029403A2 (pt) 2012-07-04 2018-10-09 F. Hoffmann-La Roche Ag conjugados, anticorpo e formulação farmacêutica
ES2895752T3 (es) 2014-01-03 2022-02-22 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
EP3089758B1 (de) 2014-01-03 2021-01-27 F.Hoffmann-La Roche Ag Kovalent verknüpfte helikar-/anti-helikar-antikörperkonjugate und verwendungen davon
EP3089759B1 (de) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Kovalent verknüpfte polypeptidtoxin-antikörperkonjugate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
FR2566271B1 (fr) * 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
WO1988007553A1 (fr) * 1987-03-26 1988-10-06 Teijin Limited Procede de preparation d'un complexe d'anticorps
AU654663B2 (en) * 1989-11-30 1994-11-17 Mallinckrodt Medical, Inc. Method for preparing a metal-radionuclide-labelled protein
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
SE9100142L (sv) * 1991-01-17 1992-07-18 Bengt Sandberg En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
EP0646019B9 (de) * 1992-06-09 2002-12-18 Neorx Corporation Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren
JPH0853499A (ja) * 1994-08-10 1996-02-27 Green Cross Corp:The キメラ抗体Ｆａｂ断片のオリゴマー体

Also Published As

Publication number Publication date
RU2219949C2 (ru) 2003-12-27
KR100485240B1 (ko) 2006-10-24
DE69724761D1 (de) 2003-10-16
DE69724761T2 (de) 2004-08-05
AU1693997A (en) 1997-08-01
EP0873139A1 (de) 1998-10-28
EP0873139B1 (de) 2003-09-10
JP2000503301A (ja) 2000-03-21
AU730388B2 (en) 2001-03-08
CA2242750C (en) 2007-03-27
CA2242750A1 (en) 1997-07-17
WO1997025069A1 (en) 1997-07-17
JP2012131808A (ja) 2012-07-12
KR19990077198A (ko) 1999-10-25
ES2206683T3 (es) 2004-05-16

Similar Documents

Publication Publication Date Title
CA2090700A1 (en) Modified antibodies with controlled clearance time
TR200101751T2 (tr) Poliol-IFN-beta konjugatları
ATE246517T1 (de) Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung
ATE517125T1 (de) ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
FR15C0033I2 (fr) Support macromoleculaire sur base de dextran pour l'administration d'un agent diagnostique ou therapeutique
DE69838979D1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
EP0329184A3 (de) Antimere und antimere Konjugation
NO901986D0 (no) Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler.
CA2118032A1 (en) Therapeutic conjugates of toxins and drugs
BR0014652A (pt) Fabricação de conjugados de agente terapêutico-poliglutamato
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
ATE369878T1 (de) Träger-pharmaka-konjugate
BR0016339A (pt) Composição de lcrf, conjugado de lcrf, composição de peptìdeo, complexo de lcrf conjugado a ligando múltiplo, complexo de polissorbato, complexo de lcrf conjugado, aquosamente solúvel estável, forma de dosagem de administração oral para o tratamento da obesidade, métodos de tratamento da obesidade em um paciente mamìfero humano ou não humano, de tratamento modo profilático ou intervencional da obesidade potencial ou desenvolvida em um paciente mamìfero humano ou não humano e de prolongamento da atividade de lcrf em um sistema in vivo ou in vitro, e, composto
NO20010021D0 (no) Trifunksjonelt reagens for konjugering til et biomolekyl
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
DE69724761D1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
DE69230970D1 (de) Bicylclische, polyazamakrocyclocarbonsäure-komplexe, konjugate, herstellung und verwendung als kontraststoffe
DE69223504D1 (de) Bicycloazamakrocyclophosphon-Säure, Komplexe, Konjugate, Kontrastmittel und Herstellung
DK0478631T3 (da) Målsøgende midler
BR0207327A (pt) Amino derivados de biotina e seus conjugados com agentes quelantes macrocìclicos
FI933506A0 (fi) Bicyklopolyazamakrocyklokarboxylsyrakomplex, konjugat daerav, foerfarande foer deras framstaellning och anvaendning som kontrastmedel
EA200100311A1 (ru) Бифункциональные антитела и их применение для прицельной доставки противоопухолевых средств
BR9714945A (pt) Composição topicamente aplicável para introdução de fármacos peptidaceosos em organismos vivos
NO954442L (no) Bicyklopolyazamakrocyklofosfonsyrer, deres komplekser og konjugater, for anvendelse som kontrastmidler, og fremgangsmåter for deres fremstilling

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0873139

Country of ref document: EP